PROCHLORPERAZINE MALEATE MARKET ANALYSIS

The Global Prochlorperazine Maleate Market size estimated to be valued at US$ 1.46 billion in 2023 and is expected to reach US$ 1.85 billion by 2030, grow at a compound annual growth rate (CAGR) of 3.4% from 2023 to 2030.

Prochlorperazine maleate is a medication belonging to the phenothiazine class of antipsychotic drugs. It is primarily used for the management of various conditions, such as severe nausea and vomiting, vertigo, and certain mental health disorders. The market for prochlorperazine maleate is driven by its effectiveness in controlling nausea and vomiting associated with chemotherapy, postoperative procedures, and other medical conditions. The drug acts by blocking dopamine receptors in the brain, thereby reducing the sensations of nausea and vomiting. Prochlorperazine maleate is available in different forms, including oral tablets, rectal suppositories, and injectable formulations, providing flexibility in administration and catering to various patient needs.

The prochlorperazine maleate market is expected to witness steady growth due to its established efficacy and widespread use in managing nausea and vomiting. The drug's versatility in treating multiple conditions contributes to its demand across various medical specialties, including oncology, gastroenterology, and neurology. Additionally, ongoing research and development efforts to enhance the drug's formulation, improve patient compliance, and explore new therapeutic indications further expand the market potential for prochlorperazine maleate.

Prochlorperazine Maleate Market Regional Insights

• North America: North America is the largest market for prochlorperazine maleate, accounting for a share of over 40.1% in 2022. North America, particularly the U.S., represents a significant market for prochlorperazine maleate. The region benefits from advanced healthcare infrastructure, a well-established pharmaceutical industry, and a large patient population. The high prevalence of conditions requiring antiemetic therapy, such as chemotherapy-induced nausea and vomiting, contributes to the demand for prochlorperazine maleate in this region.
• Europe: Europe is the second-largest market for prochlorperazine maleate, accounting for a share of over 30.9% in 2022. Europe is another prominent market for prochlorperazine maleate. Countries such as the U.K., Germany, France, and Italy have well-developed healthcare systems and a strong emphasis on managing symptoms like nausea and vomiting. The presence of a sizable patient population, along with the availability of a diverse range of healthcare services, supports the market growth of prochlorperazine maleate in Europe.
• Asia Pacific: Asia Pacific is the fastest-growing market for prochlorperazine maleate, accounting for 23.2% market share in 2022. The Asia Pacific region is witnessing significant growth in the prochlorperazine maleate market. Factors such as the rising prevalence of chronic diseases, increasing healthcare expenditure, and improving access to healthcare facilities contribute to the market expansion. Countries like China, Japan, India, and Australia are key contributors to the growth of the prochlorperazine maleate market in this region.

Figure 1. Global Prochlorperazine Maleate Market Share (%), by Region, 2023

To learn more about this report, request sample copy

Analysts’ Views on Global Prochlorperazine Maleate Market:

Prochlorperazine maleate is an antiemetic and antipsychotic medication, primarily used to control severe nausea and vomiting, as well as to treat symptoms of schizophrenia. It works by blocking or lessening the effects of dopamine, a chemical in the brain that can become imbalanced in certain conditions. The global prochlorperazine maleate market is expected to witness significant growth in the coming years. This growth is primarily driven by the increasing prevalence of mental health disorders and conditions causing severe nausea and vomiting, such as migraines and vertigo. The rising awareness about mental health and the availability of effective treatments are also contributing to market growth.

Prochlorperazine Maleate Market Drivers:

• Increasing Prevalence of Nausea and Vomiting: Nausea and vomiting are common symptoms experienced by patients undergoing chemotherapy, surgery, and other medical procedures. With the growing prevalence of chronic diseases and an aging population, the number of individuals requiring antiemetic therapy is increasing. Prochlorperazine maleate, with its proven effectiveness, becomes a preferred choice for healthcare providers in managing these symptoms, leading to market growth. For instance, according to the data published by Science Direct in October 2021, a study conducted to determine the prevalence and coping strategies for postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting (PDNV) in patients undergoing outpatient surgery, it was found that 30.6% of the patients had PONV and 26.3% had PDNV.
• Increasing Product Launches: Increasing product launches by market players is expected to propel market growth over the forecast period. For instance, on March 20, 2023, Glenmark Pharmaceuticals, a pharmaceutical company based in India, received approval from the U.S. Food and Drug Administration (FDA) for Prochlorperazine Maleate Tablets USP, 5 mg, and 10 mg.

Prochlorperazine Maleate Market Opportunities:

• Increasing Prevalence of Mental Disorder: Increasing prevalence of mental illness is expected to propel market growth over the forecast period. For instance, according to the data published by the World Health Organization on January 10, 2022, schizophrenia affects approximately 24 million people, or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults.
• Expansion into Emerging Markets: There is a significant opportunity for prochlorperazine maleate manufacturers to expand their presence in emerging markets. Regions such as Asia Pacific, Latin America, and the Middle East have growing healthcare infrastructure, increasing access to medical services, and a rising prevalence of conditions requiring antiemetic therapy. By targeting these markets and adapting to local regulations and preferences, companies can tap into new customer bases and drive market growth.

Prochlorperazine Maleate Market Trends:

• Increasing Product Launches: Pharmaceutical companies are investing and launching new products in the market, which is expected to propel market growth over the forecast period.

For instance, on August 29, 2022, ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg.

Prochlorperazine Maleate Market Restraints:

• Availability of Alternative Therapies: There are alternative therapies and medications available for managing nausea and vomiting, which can limit the market potential of prochlorperazine maleate. Other antiemetic drugs, such as 5-HT3 receptor antagonists or NK-1 receptor antagonists, may be preferred in certain clinical scenarios based on patient characteristics or specific indications. The availability of these alternatives may influence the prescribing patterns and market demand for prochlorperazine maleate.
• Increasing product launches by the market players will aid in the market growth over the forecast period.

Recent Developments

New product launches

• On August 11, 2022, Zydus Lifesciences, a pharmaceutical company based in India received final approval from the U.S. FDA to market market Prochlorperazine Maleate tablets, USP 5 mg, and 10 mg.

Acquisition and partnerships

• On August 29, 2022, ANI Pharmaceuticals, Inc. announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg., ANI’s Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg are the generic version of the Reference Listed Drug (RLD) Compazine and were developed in technical collaboration with Biophore India Pharmaceuticals Pvt. Ltd., a pharmaceutical company based in India.

Figure 2. Global Prochlorperazine Maleate Market Share (%), by Dosage Form, 2023

To learn more about this report, request sample copy

Top companies in Prochlorperazine Maleate Market

• Sandoz Inc.
• Mylan Pharmaceuticals Inc.
• Amneal Pharmaceuticals LLC
• Glenmark Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Aspen Pharma Trading Limited
• FAGRON
• Sanofi
• GlaxoSmithKline
• Hikma Pharmaceuticals

Definition: Prochlorperazine maleate is a medication that belongs to the phenothiazine class of antipsychotic drugs. It is primarily used to manage conditions such as severe nausea and vomiting, vertigo, and certain mental health disorders. Prochlorperazine maleate works by blocking dopamine receptors in the brain, reducing the sensations of nausea and vomiting.